Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of $772.16 million. The enterprise value is $774.47 million.
Important Dates
The last earnings date was Thursday, July 31, 2025, before market open.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 685.15 million shares outstanding. The number of shares has increased by 1.47% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 685.15M |
| Shares Change (YoY) | +1.47% |
| Shares Change (QoQ) | +2.60% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 670.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 46.92 |
| PS Ratio | 2.27 |
| Forward PS | 4.28 |
| PB Ratio | 3.22 |
| P/TBV Ratio | 7.45 |
| P/FCF Ratio | 25.62 |
| P/OCF Ratio | 24.87 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 29.37, with an EV/FCF ratio of 25.69.
| EV / Earnings | n/a |
| EV / Sales | 2.28 |
| EV / EBITDA | 29.37 |
| EV / EBIT | 39.43 |
| EV / FCF | 25.69 |
Financial Position
The company has a current ratio of 2.79, with a Debt / Equity ratio of 0.54.
| Current Ratio | 2.79 |
| Quick Ratio | 2.04 |
| Debt / Equity | 0.54 |
| Debt / EBITDA | 4.35 |
| Debt / FCF | 4.26 |
| Interest Coverage | 1.91 |
Financial Efficiency
Return on equity (ROE) is -3.70% and return on invested capital (ROIC) is 3.45%.
| Return on Equity (ROE) | -3.70% |
| Return on Assets (ROA) | 2.85% |
| Return on Invested Capital (ROIC) | 3.45% |
| Return on Capital Employed (ROCE) | 5.48% |
| Revenue Per Employee | $841,178 |
| Profits Per Employee | -$20,297 |
| Employee Count | 404 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 0.59 |
Taxes
In the past 12 months, Pharming Group has paid $12.00 million in taxes.
| Income Tax | 12.00M |
| Effective Tax Rate | 344.42% |
Stock Price Statistics
The stock price has increased by +47.64% in the last 52 weeks. The beta is 0.54, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +47.64% |
| 50-Day Moving Average | 10.92 |
| 200-Day Moving Average | 9.36 |
| Relative Strength Index (RSI) | 51.06 |
| Average Volume (20 Days) | 11,056 |
Short Selling Information
| Short Interest | 5,210 |
| Short Previous Month | 1,098 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 0.97 |
Income Statement
In the last 12 months, Pharming Group had revenue of $339.84 million and -$8.20 million in losses. Loss per share was -$0.01.
| Revenue | 339.84M |
| Gross Profit | 303.51M |
| Operating Income | 19.64M |
| Pretax Income | -15.41M |
| Net Income | -8.20M |
| EBITDA | 26.37M |
| EBIT | 19.64M |
| Loss Per Share | -$0.01 |
Full Income StatementBalance Sheet
The company has $126.01 million in cash and $128.33 million in debt, giving a net cash position of -$2.32 million or -$0.00 per share.
| Cash & Cash Equivalents | 126.01M |
| Total Debt | 128.33M |
| Net Cash | -2.32M |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | 239.55M |
| Book Value Per Share | 0.35 |
| Working Capital | 157.83M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $31.05 million and capital expenditures -$906,000, giving a free cash flow of $30.14 million.
| Operating Cash Flow | 31.05M |
| Capital Expenditures | -906,000 |
| Free Cash Flow | 30.14M |
| FCF Per Share | $0.04 |
Full Cash Flow StatementMargins
Gross margin is 89.31%, with operating and profit margins of 5.78% and -2.41%.
| Gross Margin | 89.31% |
| Operating Margin | 5.78% |
| Pretax Margin | 1.02% |
| Profit Margin | -2.41% |
| EBITDA Margin | 7.76% |
| EBIT Margin | 5.78% |
| FCF Margin | 8.87% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.47% |
| Shareholder Yield | -1.47% |
| Earnings Yield | -1.06% |
| FCF Yield | 3.90% |
Analyst Forecast
The average price target for Pharming Group is $30.00, which is 166.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.00 |
| Price Target Difference | 166.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 9.79% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharming Group has an Altman Z-Score of 2.24 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.24 |
| Piotroski F-Score | 5 |